Skip to main content
Log in

Pharmacokinetics and Pharmacodynamics of an Investigational Antipsychotic Agent, CI-1007, in Rats and Monkeys

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose. To study the pharmacokinetics (PK) and pharmacodynamics (PD) of an investigational antipsychotic agent, CI-1007, in rats and monkeys.

Methods. CI-1007 and a pharmacologically active metabolite, PD 147693 (Ml), were evaluated in animal antipsychotic tests (inhibition of dopamine neuron firing and spontaneous locomotor activity in rats, and inhibition of continuous avoidance in monkeys). Plasma concentrations of CI-1007 and Ml were determined using validated HPLC assays. Log-linear and link models were used for PK/PD analysis.

Results. CI-1007 and Ml have shown similar effects on dopamine neuron firing (2.5 mg/kg i.p.), and produced dose-related effects on spontaneous locomotor activity in rats (0.3−30 mg/kg, p.o.) and on continuous avoidance in monkeys (0.6−1.2 mg/kg p.o.). After pharmacologically active CI-1007 doses, mean plasma CI-1007 Cmax increased from 19 to 200 ng/ml in Sprague-Dawley rats at doses of 3−30 mg/ kg, and from 8.1 to 34 ng/ml in squirrel monkeys at doses of 0.6−1.2 mg/kg, but corresponding plasma M1 Cmax values were near or below the limit of quantitation (5 ng/ml). CI-1007 EC50 was 31.1 ng/ml in rats, calculated from a log-linear regression. In monkeys, CI-1007 ECe50, γ, and Keo at 0.6 and 1.2 mg/kg were 4.8 and 4.5 ng/ml, 1.9 and 2.0, and 0.47 and 0.48 hr−1, respectively, calculated by the link model.

Conclusions. CI-1007 has shown dose-related pharmacokinetics and pharmacodynamics in rats and monkeys. Although Ml produces anti-psychotic-like effects similar to CI-1007, the contribution of Ml to the activity of the parent drug may not be significant in rats and monkeys as based on plasma levels. CI-1007 plasma concentration correlates log-linearly with inhibition effect from the rat locomotor study. The counter-clockwise hysteresis relationship of CI-1007 plasma concentration and inhibition effect from the monkey avoidance test was described by a link model, and the resulting Ce (concentration in effect compartment) versus effect profile exhibits a sigmoidal curve.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

REFERENCES

  1. T. Pugsley, D. Davis, C. Akunne, L. Cooke, S. Whetzel, R. Mackenzie, Y. Shih, D. Van Leeuwen, L. Demattos, B. Caprathe, J. Wright, J. Jean, L. Wise, and T. Heffner. J. Pharmacol. Exp. Ther. 274:898–911 (1995).

    Google Scholar 

  2. L. Meltzer, C. Christoffersen, A. Corbin, F. Ninteman, K. Serpa, J. N. Wiley, L. Wise, and T. Heffner. J. Pharmacol. Exp. Ther. 274:912–920 (1995).

    Google Scholar 

  3. M. Rose Feng, C. Strenkoski, T. Parker, and D. S. Wright. Pharm Res. 10:S-320 (1993).

    Google Scholar 

  4. M. Rose Feng, S. Bezek, A. Gandhi, C. Strenkoski, T. Woolf, and D. S. Wright. Pharm Res. 10:S-347 (1994).

    Google Scholar 

  5. J. Wright, D. Downing, M. Rose Feng, R. Hayes, T. Heffner, R. Mackenzie, L. Meltzer, T. Pugsley, and L. Wise. J. Med. Chem. 38:5007–5014, (1995).

    Google Scholar 

  6. T. Heffner, D. Downs, L. Meltzer, J. Wiley, and A. Williams. J. Pharmacol. Exp. Ther. 251:105–112 (1989).

    Google Scholar 

  7. M. Rose Feng, P. Siersma, C. Strenkoski, and D. S. Wright. J. Chromatogr. B. 665:193–199 (1995).

    Google Scholar 

  8. L. Sheiner, D. Stanski, S. Vozeh, R. Miller, and J. Ham. Clin. Pharmacol Ther 3:358–371 (1979).

    Google Scholar 

  9. D. Verotta and L. Sheiner. J. Pharmacokin Biopharm 23(1):1–4 (1995).

    Google Scholar 

  10. M. Rose Feng, W. Mcnally, and L. Meltzer, unpublished data.

  11. C. Walker. Drug metab Rev. 2:295–323, (1978).

    Google Scholar 

  12. M. Sinz, B. Michniewicz, and T. Woolf. Metabolic and species comparison of the antipsychotic agent CI-1007 using microsomes, hepatocyte, and purified enzymes. Poster for 4th International ISSX, Seattle, WA, 1995.

  13. Wagner J (1993) Pharmacokinetics for the pharmaceutical scientist, Technomic, Lancaster—Basel.

    Google Scholar 

  14. J. Javaid. J. Clin. Pharmacol. 34:286–295 (1994).

    Google Scholar 

  15. A. Jørgensen. In J. W. Bridges and L. F. Chasseaud (eds.), Progress in Drug Metabolism. Taylor & Francis Ltd, 1986, Vol. 9, p 111–173.

  16. W. Meuldermans, J. Hendrick, G. Mannen, K. Lavrijsen, C. Janssen, J. Bracke, L. Jeune, W. Lauwers, and J. Heykans. Drug Met. Dispos. 1:129–138 (1994).

    Google Scholar 

  17. O. Őgren, J. Laudstrőm, and B. Nilsson. J. Neural Transm. 94:199–216 (1993).

    Google Scholar 

  18. Stephen R. Marder, John M. Davis, Philip G. Janicak. Clinical use of neuroleptic plasma levels. American Psychiatric Press, Inc, Washington DC, 1993.

    Google Scholar 

  19. P. Snoeck, A. Peer, M. Horton, G. Mannens, R. Woestenborghs, R., Meibach, J. Heykants. Psychopharmacology 122:223–229 (1995).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Meihua Rose Feng.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Feng, M.R., Corbin, A.E., Wang, Y. et al. Pharmacokinetics and Pharmacodynamics of an Investigational Antipsychotic Agent, CI-1007, in Rats and Monkeys. Pharm Res 14, 329–336 (1997). https://doi.org/10.1023/A:1012050121937

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1012050121937

Navigation